Original Article

You have full text access to this OnlineOpen article

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

  1. Sarah Danson1,†,*,
  2. Mark R. Middleton Ph.D.1,
  3. Kenneth J. O'Byrne2,
  4. Mark Clemons1,
  5. Malcolm Ranson Ph.D.1,
  6. Jurjees Hassan1,
  7. Heather Anderson1,3,
  8. Paul A. Burt4,
  9. Corrine Fairve-Finn4,
  10. Ronald Stout4,
  11. Isabel Dowd R.G.N.1,
  12. Linda Ashcroft M.Sc.1,
  13. Cheryl Beresford R.G.N.3,
  14. Nicholas Thatcher Ph.D.1,3,‡

Article first published online: 16 JUN 2003

DOI: 10.1002/cncr.11535

Issue

Cancer

Cancer

Volume 98, Issue 3, pages 542–553, 1 August 2003

Additional Information

How to Cite

Danson, S., Middleton, M. R., O'Byrne, K. J., Clemons, M., Ranson, M., Hassan, J., Anderson, H., Burt, P. A., Fairve-Finn, C., Stout, R., Dowd, I., Ashcroft, L., Beresford, C. and Thatcher, N. (2003), Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. Cancer, 98: 542–553. doi: 10.1002/cncr.11535

Author Information

  1. 1

    Department of Medical Oncology, Christie Hospital National Health Service Trust, Manchester, United Kingdom

  2. 2

    University Department of Oncology, Leicester Royal Infirmary, Leicester, United Kingdom

  3. 3

    Department of Oncology, Wythenshawe Hospital, Manchester, United Kingdom

  4. 4

    Holt Radium Institute, Christie Hospital National Health Service Trust, Manchester, United Kingdom

  1. †

    Fax: (011) 44 1614463299

  2. ‡

    Nicholas Thatcher received less than $2000 per year from Eli Lilly and Company for research support and for acting as a consultant.

*Department of Medical Oncology, Christie Hospital National Health Service Trust, Wilmslow Road, Withington, Manchester, M20 4BX, United Kingdom

Publication History

  1. Issue published online: 18 JUL 2003
  2. Article first published online: 16 JUN 2003
  3. Manuscript Accepted: 16 APR 2003
  4. Manuscript Revised: 2 APR 2003
  5. Manuscript Received: 12 NOV 2002

Funded by

  • Eli Lilly and Company

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (325K)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Everardo D. Saad, Krzysztof Adamowicz, Artur Katz, Jacek Jassem, Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials, Cancer Treatment Reviews, 2012,

    CrossRef

  2. 2
    Peter Mazzone, Tarek Mekhail, Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists, Respiratory Medicine, 2012, 106, 4, 473

    CrossRef

  3. 3
    P. Wheatley-Price, F. Blackhall, S.- M. Lee, C. Ma, L. Ashcroft, M. Jitlal, W. Qian, A. Hackshaw, R. Rudd, R. Booton, S. Danson, P. Lorigan, N. Thatcher, F. A. Shepherd, The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials, Annals of Oncology, 2010, 21, 10, 2023

    CrossRef

  4. 4
    Giulio Metro, Federico Cappuzzo, New targeted therapies for non-small-cell lung cancer, Therapy, 2009, 6, 3, 335

    CrossRef

  5. 5
    Cathy CROMBIE, W Ivon BURNS, Christos KARAPETIS, Ray M LOWENTHAL, Fred KIRSTEN, J Andrew DAVIDSON, Fiona ABELL, William HH REECE, Jose IGLESIAS, Paul DE SOUZA, Randomized phase II trial of gemcitabine and either day 1 or day 8 carboplatin for advanced non-small-cell lung cancer: Is thrombocytopenia predictable?, Asia-Pacific Journal of Clinical Oncology, 2009, 5, 1
    Direct Link:
  6. 6
    Jonathan K Reynolds, Terri L Levien, Quality-of-Life Assessment in Phase III Clinical Trials of Gemcitabine in Non-Small-Cell Lung Cancer, Drugs & Aging, 2008, 25, 11, 893

    CrossRef

  7. 7
    Karin Pat, Christophe Dooms, Johan Vansteenkiste, Systematic review of symptom control and quality of life in studies on chemotherapy for advanced non-small cell lung cancer: How CONSORTed are the data?, Lung Cancer, 2008, 62, 1, 126

    CrossRef

  8. 8
    Jean-Paul Sculier, Anne-Pascale Meert, Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis, Journal of Thoracic Oncology, 2008, 3, 3, 320

    CrossRef

  9. 9
    Thomas E. Stinchcombe, Daniel B. Fried, Maria Q. Baggstrom, Thomas A. Hensing, Mark A. Socinski, Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis, Journal of Thoracic Oncology, 2008, 3, 3, 320

    CrossRef

  10. 10
    Jingwei Jiang, Xiaohua Liang, Xinli Zhou, Ruofan Huang, Zhaohui Chu, A meta-analysis of randomized controlled trials comparing carboplatin-based to cisplatin-based chemotherapy in advanced non-small cell lung cancer, Lung Cancer, 2007, 57, 3, 348

    CrossRef

  11. 11
    Yoshio Tomizawa, Shin-ichi Ishihara, Hironobu Iijima, Hisao Imai, Koji Sato, Masakiyo Yatomi, Yasuki Iwasaki, Hidenori Yamada, Go Kobayashi, Emi Ishida, Teruki Inoue, Haruka Aoki, Satoru Watanabe, Osamu Kawashima, Masatomo Mori, Ryusei Saito, A Phase I Dose Escalation Study of Biweekly Gemcitabine and Carboplatin in Completely Resected Stage IB-IIIA Nonsmall Cell Lung Cancer, American Journal of Clinical Oncology, 2007, 30, 5, 498

    CrossRef

  12. 12
    Arkadiusz Z. Dudek, Timothy Larson, Mani Keshtgarpour, Priya Kumar, Dose Escalating Study of Biweekly Gemcitabine and Carboplatin in Patients With Advanced Cancer, American Journal of Clinical Oncology, 2007, 30, 5, 481

    CrossRef

  13. 13
    Sylke Nagel, Raffaele Califano, Nicholas Thatcher, Fiona Blackhall, Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer, Expert Opinion on Pharmacotherapy, 2007, 8, 18, 3265

    CrossRef

  14. 14
    S. Baka, C. Manegold, E. Buchholz, K. Schott-von-Römer, P. Lorigan, S. Nagel, F. Blackhall, L. Aschroft, N. Thatcher, Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer, Lung Cancer, 2006, 53, 2, 165

    CrossRef

  15. 15
    Chandra P. Belani, Jose R. Pereira, Joachim von Pawel, Anna Pluzanska, Vera Gorbounova, Eckhard Kaukel, Karin V. Mattson, Rodryg Ramlau, Aleksandra Szczesna, Panos Fidias, Michael Millward, Frank Fossella, Effect of chemotherapy for advanced non-small cell lung cancer on patients’ quality of life, Lung Cancer, 2006, 53, 2, 231

    CrossRef

  16. 16
    Jeffrey A. Jones, Elenir B. C. Avritscher, Catherine D. Cooksley, Marisol Michelet, B. Nebiyou Bekele, Linda S. Elting, Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer, Supportive Care in Cancer, 2006, 14, 6, 505

    CrossRef

  17. 17
    M. Reck, K.M. Deppermann, U. Gatzemeier, N. Niederle, Nichtkleinzelliges Lungenkarzinom, Der Onkologe, 2006, 12, 8, 761

    CrossRef

  18. 18
    Paul Ritch, Charles M. Rudin, Jacob David Bitran, Martin J. Edelman, Alex Makalinao, David Irwin, Rogerio Lilenbaum, Patrick Peterson, William J. John, Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer, Lung Cancer, 2006, 52, 2, 173

    CrossRef

  19. 19
    P. Thomas, G. Robinet, S. Gouva, P. Fournel, H. Léna, H. Le Caer, M. Perol, H. Berard, P. Bombaron, A. Vergnenegre, J.P. Kleisbauer, Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer, Lung Cancer, 2006, 51, 1, 105

    CrossRef

  20. 20
    Michael Bergqvist, Sverre S??renson, Daniel Brattstr??m, Tony Mok, Roger Henriksson, Role of Non-Taxane-Containing Chemotherapy in Advanced Non-Small Cell Lung Cancer, American Journal of Cancer, 2006, 5, 4, 223

    CrossRef

  21. 21
    Christophe A Dooms, Karin E Pat, Johan F Vansteenkiste, The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small cell lung cancer, Expert Review of Anticancer Therapy, 2006, 6, 4, 531

    CrossRef

  22. 22
    Daniel T. Milton, Vincent A. Miller, Advances in Cytotoxic Chemotherapy for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer, Seminars in Oncology, 2005, 32, 3, 299

    CrossRef

  23. 23
    Lesley J. Fallowfield, Peter Harper, Health-related quality of life in patients undergoing drug therapy for advanced non-small-cell lung cancer, Lung Cancer, 2005, 48, 3, 365

    CrossRef

  24. 24
    L Toschi, G Finocchiaro, S Bartolini, V Gioia, F Cappuzzo, Role of gemcitabine in cancer therapy, Future Oncology, 2005, 1, 1, 7

    CrossRef

  25. 25
    Giuseppe Giaccone, Egbert Smit, Cancer Chemotherapy and Biological Response Modifiers Annual Volume 22, 2005,

    CrossRef

  26. 26
    Martin Reck, Ulrich Gatzemeier, Chemotherapy in stage-IV NSCLC, Lung Cancer, 2004, 45, S217

    CrossRef

  27. 27
    T Kurata, K Tamura, N Yamamoto, T Nogami, T Satoh, H Kaneda, K Nakagawa, M Fukuoka, Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer, British Journal of Cancer, 2004,

    CrossRef

  28. 28
    Joseph B Zwischenberger, Roger A Vertrees, Eric A Bedell, Christopher K McQuitty, Jill M Chernin, Lee C Woodson, Percutaneous venovenous Perfusion-Induced systemic hyperthermia for lung cancer: a phase I safety study, The Annals of Thoracic Surgery, 2004, 77, 6, 1916

    CrossRef

  29. 29
    Christophe A Dooms, Johan F Vansteenkiste, Treatment of Patients with Advanced Non-Small Cell Lung Cancer, American Journal of Cancer, 2004, 3, 5, 281

    CrossRef

  30. 30
    Catherine Delbaldo, Stefan Michiels, Estelle Rolland, Nathalie Syz, Jean-Charles Soria, Thierry Le Chevalier, Jean Pierre Pignon, Second or third additional chemotherapy drug for non-small cell lung cancer in patients with advanced disease, The Cochrane Library,
    Direct Link:
View Full Article (HTML) Get PDF (325K)